Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that mitotane causes specific changes in cortisol metabolism, including increased excretion of certain metabolites, which may influence cortisol bioavailability without hindering early detection of adrenocortical carcinoma recurrence.

This observational study in Bogotá found that skin issues like acne and androgenetic alopecia are common among adults with gender dysphoria on hormone therapy, emphasizing the need for dermatological care as part of comprehensive treatment.

This study found that serum vaspin levels were elevated in women with polycystic ovary syndrome compared to controls, but treatment with metformin or weight loss did not significantly change these levels.

This study found that transdermal DHT treatment increased penile length in boys with 5α-reductase type 2 deficiency, but post-pubertal growth was limited and carried potential prostate complications.

This case study suggests that long-term treatment with buprenorphine/naloxone for opioid addiction may lead to secondary adrenal insufficiency, warranting further investigation.

This case report suggests that a supplement containing biotin, beta carotene, vitamin C, zinc, and copper may improve insulin resistance markers and hair loss in a patient with non-classic 11-hydroxylase deficiency.

In this case study, the use of somatostatin analogues was effective in localizing and confirming a neuroendocrine lung tumor as the source of ectopic ACTH syndrome, leading to marked clinical improvement in a patient unable to undergo surgery.

This review discusses emerging concepts in PCOS from the AEPCOS 2010 meeting and reports no clinical findings; it suggests that the transition of care in congenital adrenal hyperplasia could inform PCOS adolescent care.

This case report highlights that a patient with resistance to thyroid hormone was misdiagnosed as having Graves’ disease, leading to unnecessary radioactive iodine treatment.

This study found that GnRH-a treatment or orchiectomy, which required significantly lower doses of oral estradiol valerate, were more effective than anti-androgens like spironolactone and finasteride in achieving target hormone levels in transgender females in India.

This review discusses the diagnostic criteria and management strategies for Polycystic Ovary Syndrome (PCOS) and highlights the need for comprehensive clinical assessment, but does not report new clinical findings.

This review discusses evidence on androgen sensitivity as a potential factor in COVID-19 disease severity, suggesting that androgen receptor interactions could influence virus entry and progression, and reports no new clinical results.

In this study, researchers found that transgender men exhibited impaired autonomic modulation during sympathetic stimulation compared to cisgender women, potentially due to testosterone treatment affecting cardiac autonomic modulation.

This study observed improvements in hair loss, acne, and BPH symptoms after addressing vitamin D and progesterone deficiencies in male patients, suggesting the potential benefits of this therapeutic approach.

This case study highlights a testosterone- and cortisol-secreting adrenal oncocytic neoplasm in an 18-year-old woman, illustrating the role of surgical excision in resolving hyperandrogenism and restoring menstruation.

This case report describes a young woman with an adrenal oncocytic tumor of uncertain malignant potential, highlighting the need for ongoing surveillance due to possible malignancy.

This review evaluates therapies for hyperandrogenism, highlighting cyproterone acetate as the preferred treatment due to its potency and tolerability in managing symptoms in women.

This study found that both finasteride and flutamide effectively reduced hirsutism in women with polycystic ovary syndrome, decreasing the Ferriman-Gallwey score and hair diameter without significant side effects.

This study found that finasteride significantly improved hirsutism scores in women over 12 months and was well-tolerated with no serious side effects.

This study found that finasteride treatment in males with androgenetic alopecia was linked to significant changes in sperm parameters and increased testosterone levels, but no sexual dysfunction was observed, and sperm parameters returned to baseline after treatment stopped.

This review discusses the effects of hormonal treatments on the physical and mental health of transgender individuals, reporting significant reductions in mental health issues following treatment, but calls for more research on long-term and nonbinary outcomes.

This review discusses the challenges in optimizing glucocorticoid treatment for classic 21-hydroxylase deficiency, emphasizing individualized care and the need for comprehensive management, but presents no new findings.

This study found that both myo-inositol and metformin helped restore normal menstrual cycles in patients with PCOS, but myo-inositol appeared to be more effective in inducing pregnancy.

This study found that myo-inositol treatment reduced hirsutism and acne in women with PCOS by improving their metabolic profiles, including lower insulin and testosterone levels.

In this study, low-dose finasteride (2.5 mg/day) significantly reduced hirsutism scores in women over 12 months without significant hormonal changes or serious side effects.

This study reports that metreleptin treatment in a boy with congenital generalized lipodystrophy significantly improved metabolic complications and overall health outcomes during the first year of therapy.

In this study, estetrol (E4) treatment was associated with increased hair growth in ex vivo human hair follicles, suggesting its potential as a treatment for hair loss disorders.

This review discusses recent advancements in understanding and managing congenital adrenal hyperplasia, including improvements in screening, diagnostics, and potential genetic and cell-based treatments, but reports no new clinical findings.

This study found that in men with benign prostatic hyperplasia, a 3-month treatment with a long-acting GnRH agonist significantly reduced intraprostatic DHT and 3α-diol levels by about 90% and testosterone by about 75%.